EAST WINDSOR, N.J. — Aurobindo Pharma USA (Aurobindo) has proposed the acquisition of Lannett Co. (Lannett). The company says it anticipates closing the acquisition towards the middle of calendar 2026, subject to regulatory approval.
"Over the coming months, we will be providing additional updates on this exciting acquisition and how we expect it to enable us to better serve you, our valued customer," said Paul McMahon, president, APUSA Oral Solids Division at Aurobindo. "In the meantime, until the transaction closes, it will be business as usual in every respect with both Aurobindo and Lannett continuing to operate as separate entities. Please continue to work with your respective points of contact at Aurobindo and Lannett for any of your normal day-to-day business needs regarding the respective product portfolios, operational and transactional matters, etc," he added.
Aurobindo to purchase Lannett Co.
The company says it anticipates closing the acquisition towards the middle of calendar 2026, subject to regulatory approval.
Latest
Harris Teeter expands GLP-1 access
Regional grocer integrates medications, dietitians and affordability tools to support weight management.
Kroger Health and Hy-Vee announce line up for 2026 Nourishing Change Conference
The conference is scheduled for June 2–4, 2026, at the Iowa Events Center in Des Moines.
Publix Q1 earnings decline as drug pricing affects results
Medicare pricing reforms weigh on pharmacy sales while core retail performance remains stable.
Pure Leaf launches new ‘Mental Focus’ sparkling iced tea
Pure Leaf is teaming up with two-time Olympic gymnast Jordan Chiles and digital wellness tool Brick to highlight the importance of finding focus when it’s needed most.